retatrutide type 2 diabetes phase 2 results FDA Approval Status 2026: Everything We Know So Far Positive Top-line Results for Retatrutide

conducted a randomized, double-blinded, placebo-controlled trial to explore the effect of liraglutide on neuropathies in patients with type 1 DM (57)

Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly

This work was supported in part by JSPS KAKENHI Grant Numbers JP23K27304, JP23K20040, JP23K17389, JP21H05262 and 24K01446 to KeH, 25K08844 and 25H01419 to ES, a grant from the Japan Agency for Medical Research and Development (AMED) (JP24ak0101182s0104 and JP24gm1510012s0202) to KeH, JST CREST to KeH and Program for the Advancement of Next-Generation Research Projects (Keio University), Academic Development Fund (Keio University Academic Development Funds) and Fukuzawa Fund (Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research) to KeH and KoH was supported by the WPI-Bio2Q STaMP program (WPI-Bio2Q, Keio University)

All rights Reserved